“Tomorrow’s Medicines: Will Translational Science Lead the Way?” Forum Now Available Online

A webinar of an expert forum on translational science is now available on the New York Academy of Sciences website.

A multimedia recording of an expert forum highlighting the meaning, challenges, and promise of translational science in guiding the future of medicine is now available on the New York Academy of Sciences website.

Translational science is an integral, innovative approach in which knowledge and information is seamlessly brought from the laboratory to the patient bedside and back again. This methodology enables researchers to convert medical findings into clinical practice quickly and efficiently to improve patient care, enhance decision-making and create the next generation of therapeutic breakthroughs.

The forum, held on November 17, featured a distinguished panel of government, regulatory and academic representatives discussing:

• What defines translational science, including tools, diagnostics and personalized therapies;
• The critical role of patients in research;
• How federal regulations for this emerging area differ around the globe; and
• The therapeutic disease areas poised for the greatest advancements in translational research.

The event was presented by the New York Academy of Sciences in partnership with MedImmune, the worldwide biologics unit for AstraZeneca.

WHAT: Webcast Replay: “Tomorrow's Medicines: Will Translational Science Lead the Way?”

WHO:

Barbara M. Alving, MD, Director of the National Center for Research Resources (NCRR) at the National Institutes of Health

ShaAvhree Buckman, MD, PhD, FAAP, Director, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Garret A. FitzGerald, MD, Chair, Department of Pharmacology and Director, the Institute for Translational Medicine and Therapeutics, University of Pennsylvania

Ruth E. March, PhD, Personalized Healthcare leader, AstraZeneca, UK

Laura K. Richman, DVM, PhD, Vice President, Research and Development-Translational Sciences at MedImmune, the biologics unit of AstraZeneca

Orla Smith, PhD, Managing Editor, Science Translational Medicine

WHERE: http://hosted.mediasite.com/mediasite/Viewer/?peid=87ea8c22e1de445d83e99e78b808cb7a1d

The New York Academy of Sciences is an independent, not-for-profit organization committed to advancing science, technology, and society worldwide since 1817. With 25,000 members in 140 countries, NYAS is creating a global community of science for the benefit of humanity. NYAS' core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions, and increase the number of scientifically informed individuals in society at large. Visit us online at www.nyas.org.

About MedImmune
MedImmune, the worldwide biologics unit for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com.